Drug Trial Radar · NCT07059221
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Jul 11, 2025
Primary completion
Mar 2027
Study completion Mar 2029
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-A2102/SHR-9839(sc) for Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Conditions
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
SHR-A2102Drug
Administration by intravenous infusion
AdebrelimabDrug
Administration by intravenous infusion
CetuximabDrug
Administration by intravenous infusion
SHR-9839(sc)Drug
Administration by Subcutaneous injection
Carboplatin / CisplatinDrug
Administration by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- RP2DTime frame: through phase IB completion, an average of 5 years
- Incidence and severity of AE(DLT)Time frame: from Day1 to 90 days after last dose
- ORRTime frame: 5 years after the last subject was enrolled in the group
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.